Amicus Historical Income Statement
| FOLD Stock | USD 9.96 0.09 0.91% |
Historical analysis of Amicus Therapeutics income statement accounts such as Other Operating Expenses of 496.5 M or Research Development of 120.4 M can show how well Amicus Therapeutics performed in making a profits. Evaluating Amicus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Amicus Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Amicus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amicus Therapeutics is a good buy for the upcoming year.
Amicus |
About Amicus Income Statement Analysis
Amicus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Amicus Therapeutics shareholders. The income statement also shows Amicus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Amicus Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Amicus Therapeutics. It is also known as Amicus Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Amicus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 496.5 M, whereas EBIT is forecasted to decline to (104.9 M).
| 2023 | 2024 (projected) | Extraordinary Items | 90K | 85.5K | Reconciled Depreciation | 7.0M | 6.3M |
Amicus Therapeutics income statement Correlations
Click cells to compare fundamentals
Amicus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amicus Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (28.2M) | 8.8M | 6.2M | 5.3M | 7.9M | 8.3M | |
| Interest Expense | 18.9M | 22.4M | 32.5M | 37.1M | 50.1M | 52.7M | |
| Other Operating Expenses | 483.0M | 504.7M | 505.4M | 533.7M | 472.9M | 496.5M | |
| Operating Income | (300.7M) | (243.9M) | (199.9M) | (204.4M) | (73.5M) | (77.2M) | |
| Ebit | (300.7M) | (251.8M) | (209.1M) | (204.9M) | (100.0M) | (104.9M) | |
| Research Development | 286.4M | 308.4M | 272.0M | 276.7M | 152.4M | 120.4M | |
| Ebitda | (329.0M) | (243.0M) | (202.9M) | (199.6M) | (92.1M) | (96.7M) | |
| Total Operating Expenses | 461.0M | 473.7M | 471.0M | 495.1M | 427.7M | 449.0M | |
| Income Before Tax | (355.9M) | (274.3M) | (241.6M) | (242.0M) | (150.1M) | (157.6M) | |
| Total Other Income Expense Net | (55.2M) | (30.4M) | (41.6M) | (37.6M) | (76.6M) | (72.8M) | |
| Net Income | (356.4M) | (276.9M) | (250.5M) | (236.6M) | (151.6M) | (159.2M) | |
| Selling General Administrative | 169.9M | 156.4M | 199.2M | 214.1M | 259.3M | 272.3M | |
| Cost Of Revenue | 22.0M | 31.0M | 34.5M | 38.6M | 37.3M | 21.6M | |
| Income Tax Expense | 478K | 2.6M | 8.9M | (5.5M) | 1.5M | 1.6M | |
| Total Revenue | 182.2M | 260.9M | 305.5M | 329.2M | 399.4M | 419.3M | |
| Gross Profit | 160.3M | 229.8M | 271.0M | 290.6M | 362.0M | 380.1M | |
| Net Income From Continuing Ops | (356.4M) | (276.9M) | (250.5M) | (236.6M) | (173.6M) | (182.3M) | |
| Non Operating Income Net Other | (33.0M) | (4.8M) | (2.6M) | 7.2M | 6.5M | 6.8M | |
| Net Income Applicable To Common Shares | (356.4M) | (276.9M) | (250.5M) | (236.6M) | (212.9M) | (223.6M) | |
| Interest Income | 10.2M | 3.2M | 509K | 3.0M | 7.4M | 5.0M | |
| Tax Provision | 478K | 2.6M | 8.9M | (5.5M) | (14.9M) | (15.7M) | |
| Net Interest Income | (8.6M) | (19.2M) | (32.0M) | (34.1M) | (41.0M) | (39.0M) | |
| Reconciled Depreciation | 4.8M | 8.8M | 6.2M | 5.3M | 7.0M | 6.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.